Analysts expect Keryx Biopharmaceuticals (NASDAQ:KERX) to post earnings per share (EPS) of ($0.19) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Keryx Biopharmaceuticals’ earnings. The lowest EPS estimate is ($0.22) and the highest is ($0.16). Keryx Biopharmaceuticals posted earnings of ($0.32) per share during the same quarter last year, which suggests a positive year over year growth rate of 40.6%. The business is expected to issue its next earnings report on Wednesday, March 7th.

On average, analysts expect that Keryx Biopharmaceuticals will report full year earnings of ($1.36) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.33). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.51) per share, with EPS estimates ranging from ($0.59) to ($0.37). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.03). The company had revenue of $15.00 million during the quarter, compared to analysts’ expectations of $18.88 million. Keryx Biopharmaceuticals had a negative return on equity of 10,954.62% and a negative net margin of 323.92%. Keryx Biopharmaceuticals’s quarterly revenue was up 138.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.39) earnings per share.

KERX has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Stifel Nicolaus cut their price target on shares of Keryx Biopharmaceuticals from $7.00 to $5.00 and set a “hold” rating on the stock in a report on Wednesday, November 8th. Finally, ValuEngine downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, November 10th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. Keryx Biopharmaceuticals currently has a consensus rating of “Hold” and an average price target of $7.35.

A number of institutional investors have recently made changes to their positions in KERX. Russell Investments Group Ltd. bought a new stake in Keryx Biopharmaceuticals in the 2nd quarter valued at about $648,000. Schwab Charles Investment Management Inc. raised its stake in Keryx Biopharmaceuticals by 1.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 441,106 shares of the biopharmaceutical company’s stock valued at $3,190,000 after acquiring an additional 4,388 shares during the period. Rhumbline Advisers raised its stake in Keryx Biopharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 99,711 shares of the biopharmaceutical company’s stock valued at $721,000 after acquiring an additional 335 shares during the period. State of Wisconsin Investment Board bought a new stake in Keryx Biopharmaceuticals in the 2nd quarter valued at about $441,000. Finally, Bank of New York Mellon Corp raised its stake in Keryx Biopharmaceuticals by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 963,054 shares of the biopharmaceutical company’s stock valued at $6,963,000 after acquiring an additional 32,687 shares during the period. Institutional investors and hedge funds own 64.82% of the company’s stock.

Shares of Keryx Biopharmaceuticals (NASDAQ KERX) traded up $0.01 during trading hours on Monday, hitting $4.71. 833,400 shares of the company were exchanged, compared to its average volume of 1,133,700. The company has a quick ratio of 3.76, a current ratio of 4.46 and a debt-to-equity ratio of 13.95. The stock has a market cap of $548.63, a P/E ratio of -3.14 and a beta of 4.92. Keryx Biopharmaceuticals has a 52 week low of $4.33 and a 52 week high of $8.38.

ILLEGAL ACTIVITY WARNING: “-$0.19 Earnings Per Share Expected for Keryx Biopharmaceuticals (KERX) This Quarter” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/0-19-earnings-per-share-expected-for-keryx-biopharmaceuticals-kerx-this-quarter/1798632.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.